in Health care
AstraZeneca Ultomiris recommended for marketing approval in EU for neuromyelitis optica spectrum disorder
UK: AstraZeneca has announced that Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). If authorised, Ultomiris would be the first and only approved long-acting C5 complement inhibitor for the treatment of AQP4 […] More
